About CorisBio
CorisBio is a Healthcare company based in Gembloux (Belgium) founded in 1996, and was acquired by Avacta in June 2023. Rapid diagnostic tests for infectious diseases are developed and commercialized. CorisBio offers products and services including BL-RED, OXA-48 K-SeT, RESIST-5, Crypto/Giardia Duo-Strip, and Influ A+B K-SeT. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Bacterial.
Company details
Coris BioConcept is engaged in the development, production and commercialization of rapid diagnostic tests for the detection of the pathogen for enteric, gastric and respiratory diseases. The company utilizes immunochromatography technology with colloidal gold particles or latex microspheres to develop their products. The tests are available in two formats: dipstick and cassette. The company also offers tests under the brand name RESIST for the detection of antibiotic-resistant bacteria. The company offers products in more than 70 countries in Europe, Asia, South America, Africa, Oceania, Ireland, United Kingdom, and Norway. It is among the leaders on the Belgian market (80).
- Headquarters Gembloux, Belgium
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website corisbio.com
- Social LinkedIn X YouTube
- Acquired by Avacta (Jun 2023)
Products & Services of CorisBio
CorisBio offers a comprehensive portfolio of products and services, including BL-RED, OXA-48 K-SeT, RESIST-5, Crypto/Giardia Duo-Strip, and Influ A+B K-SeT.
Detects beta lactamases via electrochemistry technology
Identifies OXA-48-like carbapenemases using lateral flow
Tests for KPC, NDM, VIM, IMP carbapenemases
Detects Cryptosporidium and Giardia parasites
Identifies Influenza A and B viruses via lateral flow
Apps and channels of CorisBio
its YouTube channel Coris BioConcept has 239 subscribers and 18 videos.
Videos from CorisBio
The most watched videos on CorisBio's YouTube channel, Coris BioConcept (239 subscribers). Click a video to play it here.
More on Coris BioConcept.
Funding Insights of CorisBio
- Total Rounds 2
- Last Round Grant — $575,645
- First Round $302,892
(Jan 2015)
- Investors Count 1
All 2 funding rounds of CorisBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $575,645 | Grant | – | – | |
| Jan 2015 | $302,892 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in CorisBio
CorisBio has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Avacta and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Developer of therapeutics and diagnostics for the treatment of cancer | 2003 | avacta.com | Wetherby, United Kingdom |
Investor details for CorisBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CorisBio
4 dated milestones of CorisBio across 27 years, from founding to its latest funding, stage changes and deals.
- Founded CorisBio is founded.
- Funding First funding round of $303K.
- Funding Latest funding round, Grant, of $576K.
- Exit Acquired by Avacta.
Web traffic of CorisBio
The website of CorisBio (corisbio.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 48.2% vs previous month
Websites whose visitors overlap most with CorisBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gefor.4t.com | gefor.4t.com | 100% | – | ||
| inbios.com | 77% | 7.6K | #3,023,221 | View details | |
digitalscope.org | digitalscope.org | 62% | #1,392,796 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Corisbio
Complete news archive for CorisBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CorisBio
CorisBio was founded in 1996 and raised its 1st funding round 19 years after it was founded.
CorisBio is headquartered in Gembloux, Belgium. It is registered at Gembloux, Namur, Belgium.
Coris BioConcept is engaged in the development, production and commercialization of rapid diagnostic tests for the detection of the pathogen for enteric, gastric and respiratory diseases. The company utilizes immunochromatography technology with colloidal gold particles or latex microspheres to develop their products. The tests are available in two formats: dipstick and cassette. The company also offers tests under the brand name RESIST for the detection of antibiotic-resistant bacteria. The company offers products in more than 70 countries in Europe, Asia, South America, Africa, Oceania, Ireland, United Kingdom, and Norway. It is among the leaders on the Belgian market (80).
CorisBio offers BL-RED, OXA-48 K-SeT, RESIST-5, Crypto/Giardia Duo-Strip, and Influ A+B K-SeT.
CorisBio has 2 investors. Key investors include Avacta, and European Union.
Yes. CorisBio was acquired by Avacta in June 2023.